HSV Vector PP1α Gene Therapy for Selective TRPV1 Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies face challenges in selectively targeting pain-related pathways due to the wide distribution of neurotransmitters and ion channels in the nervous system, leading to tolerance, abuse, and side effects, particularly for chronic pain conditions like arthritis, cancer, and neuropathic pain, where TRPV1 channels play a significant role.
Innovation Solution
A novel gene therapy using a replication-defective HSV vector expressing the PP1α protein, which specifically targets TRPV1 channels without affecting TRPM8 or TRPA1, thereby reducing TRPV1 sensitization and associated pain without altering normal sensations like cold responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic drugs are used to target pain-related pathways, then pain relief is achieved, but selectivity is reduced leading to tolerance, abuse, and side effects
Solution Approach 1:
The invention segments the nervous system targeting approach by using a replication-defective HSV vector to deliver the PP1α phosphatase specifically to TRPV1-expressing nociceptive neurons. This localized gene therapy approach separates the therapeutic action from systemic circulation, enabling pain relief at the site of action while avoiding widespread side effects associated with systemic drug administration.
Solution Approach 2:
The HSV vector system provides local quality by directing PP1α expression specifically to TRPV1-positive sensory neurons in the peripheral nervous system. The vector's neurotropic properties ensure that the therapeutic gene is expressed only in target cells expressing TRPV1, creating localized high concentrations of the therapeutic agent where it is needed while maintaining selectivity and minimizing off-target effects.
2Adaptability or versatility
If broad-spectrum pain inhibitors are used, then multiple pain pathways are affected, but specificity for TRPV1 is reduced
Solution Approach 1:
The HSV vector acts as an intermediary delivery system that carries the PP1α gene specifically to TRPV1-expressing neurons. The vector's ability to infect sensory neurons and the subsequent expression of PP1α creates a targeted therapeutic effect on TRPV1 channels without affecting other ion channels or neurotransmitter systems, thereby achieving high specificity while maintaining therapeutic versatility across different TRPV1-mediated pain conditions.
Solution Approach 2:
The invention changes the parameter of molecular specificity by using PP1α phosphatase, which specifically dephosphorylates TRPV1 channels. This enzymatic action selectively reduces TRPV1 activity without affecting other TRP channels or neuronal functions, achieving precise targeting of TRPV1-mediated pain pathways while preserving normal sensory functions mediated by other channels.
3Reliability
If TRPV1 activity is reduced to treat pain, then pain signaling is attenuated, but normal sensory functions may be altered
Solution Approach 1:
The PP1α phosphatase is expressed at levels sufficient to attenuate TRPV1-mediated pain signaling but not so high as to completely abolish TRPV1 function. This partial action approach reduces pathological pain transmission while preserving enough TRPV1 activity to maintain normal protective sensory functions, such as heat avoidance and nociceptive reflexes, thereby treating pain without eliminating normal sensory responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PP1α gene therapy effectively reduces TRPV1-associated pain in various pain models, including arthritis, post-herpetic neuralgia, and inflammatory pain, while preserving normal sensory functions, demonstrating specificity and safety by not interfering with TRPM8 or TRPA1 responses.
Implementation Method 1
TRPV1 activity is also modulated in the opposite manner (i.e. desensitization) via dephosphorylation of residues located in the cytosolic domains of the receptor. An established example of a desensitizing molecule is calcineurin, a Ca2+-calmodulin-dependent serine/threonine protein phosphatase
Implementation Method 2
We have previously used replication-defective HSV-based gene therapy vectors to deliver inhibitory neurotransmitters or gene products that attenuate the action of pro-nociceptive molecules to primary neuronal afferents of the peripheral nervous system
Implementation Method 3
TRPV1 can be induced by binding of the agonist capsaicin, as well as by protons and temperatures above 42° C.
Implementation Method 4
TRPV1 can be induced by binding of the agonist capsaicin
Data Source
AI summary
The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1α in neurons. The invention also provides HSV vectors for expressing PP1α within neurons and compositions comprising such vectors.